SARASOTA, Fla. and BALTIMORE, Oct. 20,
2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:
INVO), a medical device company focused on
commercializing the world's only in vivo Intravaginal Culture
System (IVC), INVOcell®, an effective and affordable treatment for
patients diagnosed with infertility, today announced that four
poster abstracts were presented discussing INVOcell at the 77th
Scientific Congress & Expo of the American Society for
Reproductive Medicine (ASRM) being held this week in Baltimore, Maryland.
Steve Shum, CEO of INVO
Bioscience, commented, "It's extremely rewarding to see our
technology highlighted at this year's ASRM. Four independent
abstracts were selected for presentation at the fertility
industry's most prominent annual meeting."
"On behalf of the entire INVO team, we sincerely appreciate the
work of the many clinicians that now support INVOcell as a solution
and thank those that contributed their independent work in
advancing the understanding of the unique capabilities of INVOcell.
These types of events and studies emphasize the opportunity we have
to democratize advanced fertility services through the unique
attributes of the INVOcell solution and bring care to the large,
underserved patient population around the world," Mr. Shum
concluded.
A summary of each poster abstract is provided below with
additional details of each available on the INVO Bioscience website
at https://invobioscience.com/resources/.
IS IN VIVO BETTER THAN IN VITRO? A COMPARISON OF SIBLING
EMBRYO DEVELOPMENT AND PREGNANCY RATES THROUGH INVOCELL AND
CONVENTIONAL IVF.
Taeshin Kim, Ph.D.,1
Callie Barnwell Gibson,
Ph.D.,1 Lauren N. C.
Johnson, MD, MSCE,1 Meaghan Bowling, MD,1 John K. Park, MD,1 Bill Meyer, MD,1 Sung Tae Kim, PhD, HCLD2
1Carolina Conceptions, Raleigh, NC; 2University Hospitals
Fertility Center/Case Western Reserve
University, Beachwood,
OH
CONCLUSIONS: Our result suggests that blastocyst formation from
INVOCELL intravaginal culture performs slightly better than that of
in vitro culture although overall number of usable blastocysts,
blastocyst development rate per inseminated oocytes, and pregnancy
outcomes are not significantly different.
USE OF INVOCELL INTRAVAGINAL EMBRYO CULTURE SYSTEM FOR FIVE
DAYS OF INCUBATION: A PROSPECTIVE STUDY OF SAFETY AND
TOLERABILITY.
Karen R. Hammond, DNP, CRNP,
Lisa J. Ray, MS, HCLD, Brittany M. Penny, NO, Nicholas A. Cataldo, MD, MPH
Innovative Fertility Specialists of Alabama, Birmingham,
AL
CONCLUSIONS: In conclusion, our study demonstrates that the
INVOcell system can be safely used for a 5-day embryo incubation
without causing vaginal irritation or mucosal injury. Our results
also verify that the system is well tolerated.
COMPARISON OF FROZEN EMBRYO TRANSFERS (FET) FOR INTRAVAGINAL
CULTURE (IVC) AND TRADITIONAL IN VITRO FERTILIZATION
(IVF).
Anthony R. Anderson, D.
HSc,1 Elizabeth A.
Williams, B.Sc.,2 Darleen
Taylor, B.Sc.,2 Francisco
Arredondo, MD MPH,3 Ursula Balthazar, M.D.2
1EmbryoDirector.com, San
Antonio, TX; 2Aspire Fertility San Antonio,
San Antonio, TX;
3Positib Fertility, Monterrey, NL, Mexico.
CONCLUSIONS: For the first time an evaluation of FET's for IVC
as compared to IVF is shown in this study. This study shows that
IVC derived embryos are comparable to conventional IVF derived
embryos and a viable treatment option. With comparable outcomes and
lower cost IVC embryos provide alternate treatment plan while
increasing access to care with improved outcomes as compared to the
low cost low success IUI and high cost high success IVF.
DUO INTRAVAGINAL CULTURE (IVC) PROVIDES A POTENTIALLY
ADVANTAGEOUS SECOND SOURCE OF EMBRYOS FOR SAME-SEX FEMALE
COUPLES.
Peter Uzelac, MD, HCLD,
Pam Yango, BS, Kirsten Eckert, WHNP, Xiaomin Yu, MSc, TS
Marin Fertility Center, Greenbrae,
CA
CONCLUSIONS: Same-sex female couples utilizing IVC should
consider each carrying an INVOcell device. This approach allows
more eggs to be cultured per cycle, requires a minimal amount of
extra pre- and post-IVC lab work and potentially safeguards against
a poor outcome in the event that one culture system fails to yield
any usable embryos.
About INVO Bioscience®
We are a medical device company focused on creating simplified,
affordable treatments for patients diagnosed with infertility. Our
solution, the INVO® Procedure, is a revolutionary in vivo method of
vaginal incubation that offers patients a more natural and intimate
experience. Our lead product, the INVOcell®, is a patented medical
device used in infertility treatment and is considered an Assisted
Reproductive Technology (ART). The INVOcell® is the first
Intravaginal Culture (IVC) system in the world used for the natural
in vivo incubation of eggs and sperm during fertilization and early
embryo development, as an alternative to traditional In Vitro
Fertilization (IVF) and Intrauterine Insemination (IUI). Our
mission is to increase access to care and expand fertility
treatment across the globe with a goal to lower the cost of care
and increase the availability of care. For more information, please
visit https://invobioscience.com/.
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation
to (and expressly disclaim any such obligation to) update or alter
our forward-looking statements, whether as a result of new
information, future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-announces-four-individual-poster-abstracts-discussing-the-benefits-of-invocell-presented-at-the-2021-american-society-for-reproductive-medicine-asrm-congress--expo-301404225.html
SOURCE INVO Bioscience, Inc.